TG Therapeutics Reports Second Quarter 2024 Financial Results and Raises BRIUMVI® (ublituximab-xiiy) Full Year Revenue Guidance

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. SPCX
2. NVDA
3. ACN
4. MU
5. APGE
6. USO
7. GOOGL
8. HOOD
9. DFTX
10. IBM

Go back to TG Therapeutics Reports Second Quarter 2024 Financial Results and Raises BRIUMVI® (ublituximab-xiiy) Full Year Revenue Guidance

TG Therapeutics (TGTX) PT Raised to $30 at JPMorgan

August 7, 2024 6:17 AM EDT

JPMorgan analyst Eric Joseph raised the price target on TG Therapeutics (NASDAQ: TGTX) to $30.00 (from $26.00) while maintaining a Overweight rating.

The analyst comments "Following TGs 2Q results and conference call we are updating our model, with takeaways from the call... More